Phase 2 Readout~quarter
Phase 2 Readout: budoprutug
- Company
- Climb Bio, Inc. (CLYM)
- Drug
- budoprutug
- Indication
- PrisMN
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.
Get real-time alerts, AI-powered analysis, and full catalyst coverage.